Name of the Procedure:

Common names: Casirivimab and Imdevimab Infusion or Injection
Technical/medical name: Intravenous infusion or subcutaneous injection of Casirivimab and Imdevimab (M0244)

Summary

The administration of casirivimab and imdevimab involves delivering these monoclonal antibodies either through an intravenous (IV) line or a subcutaneous (under the skin) injection, followed by monitoring the patient for any adverse reactions. The procedure can be done from the comfort of the patient's home.

Purpose

Casirivimab and imdevimab are administered to patients who have contracted COVID-19 to help prevent severe illness. The treatment aims to reduce the risk of hospitalization and complications from the virus.

Indications

• Mild to moderate COVID-19 symptoms
• Positive COVID-19 test
• High risk of progressing to severe COVID-19 based on factors such as age, underlying health conditions, or immunocompromised status

Preparation

• No specific fasting instructions are required.
• Patients should inform their healthcare provider about any medications they're taking and any allergies.
• Baseline assessments of symptoms and vital signs may be conducted.

Procedure Description

1. Preparation: The healthcare professional will prepare the IV line or subcutaneous injection site.
2. Administration: Casirivimab and imdevimab are either infused through an IV line or injected subcutaneously.
3. Post-Administration Monitoring: The patient will be monitored for at least one hour to observe for any adverse reactions. Equipment for managing allergic reactions, including epinephrine, will be on hand.

Duration

The procedure typically takes about 2-3 hours, including preparation, administration, and post-procedure monitoring.

Setting

The procedure is performed in the patient’s home, which may have been temporarily designated as provider-based care to the hospital.

Personnel

• Registered Nurse (RN) or other qualified healthcare professionals for administration and monitoring
• Supervising Physician available for consultation as needed

Risks and Complications

• Common risks: mild pain or discomfort at the injection site, temporary minor side effects such as headache or fatigue
• Rare risks: serious allergic reactions, including anaphylaxis
• Management: Immediate medical attention and intervention if serious reactions occur

Benefits

• Reduced risk of severe COVID-19 complications
• Lower likelihood of hospitalization
• Benefits are typically realized within a few days as symptoms improve

Recovery

• Post-procedure rest is generally recommended.
• Patients should remain hydrated and take prescribed medications as directed.
• Follow-up appointments may be scheduled to assess the patient’s response to treatment.

Alternatives

• Other monoclonal antibody treatments or antiviral medications
• Hospital-based care if home administration is not feasible
• Pros and cons: Alternative treatments may have different modes of administration, availability, and efficacy profiles.

Patient Experience

• During the procedure: The patient may feel a brief sting at the injection site or the insertion of the IV needle.
• After the procedure: Common feelings include slight fatigue and localized irritation. Pain management options, such as over-the-counter analgesics, may be provided to ensure comfort.